The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trials targeting kinases operative in myeloid malignancies such as acute myeloid leukemia (AML), and luxeptinib (CG-806), which is in Phase 1a/b clinical trial in patients with relapsed or refractory B cell malignancies and AML. Tuspetinib represents the primary development focus with an $11.1 million facility agreement for clinical operations expenses.
Cyborg Score Rationale
The company reported Q3 GAAP EPS of -$2.01 with shares trading between $1.02-$12.60 over 52 weeks. While tuspetinib shows promising clinical trial data in combination therapies for AML, the pending acquisition significantly impacts equity value considerations and near-term development trajectory.
Top Insights
Tuspetinib in combination with venetoclax and azacitidine achieved complete remission/CRh responses in 100% of patients (6/6) at higher dose levels, exceeding the 66% expected from venetoclax and azacitidine alone
Company is undergoing acquisition by South Korean pharma giant Hanmi Pharmaceutical with shareholder vote reconvened to March 31, 2026 after SEC comments
Strategic partnerships include license agreements with CrystalGenomics and National Cancer Institute for clinical development
Company operates with a lean team of 13 employees as a clinical-stage entity
Named Competitors
Venetoclax/Azacitidine combination — Established standard of care for AML that tuspetinib aims to enhance
FLT3 inhibitors (gilteritinib, midostaurin) — Competing kinase inhibitors for AML and FLT3-mutated disease
BTK inhibitors (ibrutinib, acalabrutinib) — Competitive therapies for chronic lymphocytic leukemia and B cell malignancies
Recent Developments
(Feb 2026) Amended arrangement agreement filed for Hanmi acquisition with special shareholder meeting reconvened to March 31, 2026
(Feb 2026) Second amended and restated $11.1 million facility agreement with Hanmi extending through May 31, 2026
(Dec 2025) Tuspetinib triple drug therapy featured at 2025 ASH Annual Meeting showing high rate of frontline clinical responses in AML
(Nov 2025) Original arrangement agreement announced for acquisition by Hanmi Pharmaceutical
Open the full interactive Aptose Biosciences Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.